Multiple Myeloma

Andrzej Jakubowiak, MD, PhD, discusses how the data from the PERSEUS Study informed the ATLAS trial in multiple myeloma.

The FDA granted 510(k) clearance to the EXENT System to aid in the diagnosis of multiple myeloma and related disorders.

Experts discuss considerations surrounding the integration of bispecific antibodies in community oncology for multiple myeloma.

Anito-cel produced high ORR and sCR/CR rates in patients with relapsed/refractory multiple myeloma.

Marc S. Raab, MD, discusses the rationale for assessing teclistamab plus daratumumab-based induction regimens in newly diagnosed multiple myeloma.

Long-term data reveal deep remissions with eque-cel, suggesting durable disease control with BCMA-directed CAR T-cell therapy in relapsed multiple myeloma.

The FDA clears subcutaneous daratumumab in smoldering myeloma, adds REMS guidelines for pexidartinib in TGCT, and more.

Surbhi Sidana, MD, and Joshua Richter, MD, discuss the FDA approval of BVd for relapsed/refractory myeloma after at least 2 prior lines of therapy.

Andrzej Jakubowiak, MD, PhD, discusses the rationale of the phase 3 ATLAS study in patients with multiple myeloma.

The FDA has approved daratumumab and hyaluronidase-fihj for the treatment of adult patients with high-risk smoldering multiple myeloma.

Hira Mian, MD, MSc, discusses why frailty should be understood as a dynamic, evolving clinical state rather than a fixed baseline characteristic for patients with multiple myeloma.

Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.

CB-011 elicited responses in patients with relapsed/refractory multiple myeloma.

Surbhi Sidana, MD, discusses belantamab mafodotin-blmf with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma.

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

Tarek Mouhieddine, MD, discusses future research directions with ferritin and ALC as biomarkers of response to bispecific antibodies in myeloma.

The FDA has cleared BVd for multiple myeloma and revumenib for NPM1-mutant AML, and granted priority review to perioperative enfortumab vedotin in MIBC.

Arlo-cel achieved a high ORR and CR rate with durable responses and favorable safety in relapsed/refractory multiple myeloma.

Teclistamab plus daratumumab improved progression-free and overall survival in relapsed/refractory multiple myeloma after 1 to 3 lines of therapy.

Marc S. Raab, MD, discusses updated MRD negativity and safety data with teclistamab plus SOC induction regimens in newly diagnosed multiple myeloma.

Joshua Richter, MD, discusses the use of next-generation CELMoDs to boost T-cell responses with bispecific antibodies or CAR T-cell therapy in myeloma.

The top 5 OncLive TV videos of the week cover insights in uterine leiomyosarcoma, myelofibrosis, polycythemia vera, breast cancer, and multiple myeloma.

The removal of REMS programs for approved CAR T-cell therapies could enable improved access and streamlined management of hematologic malignancies.

Daratumumab plus lenalidomide, with reduced exposure to dexamethasone, led to a PFS improvement in frail, newly diagnosed multiple myeloma.